Yeshiva University: Attacking Pediatric Brain Cancer
June 16, 2020
June 16, 2020
BRONX, New York, June 16 -- Yeshiva University's Albert Einstein College of Medicine issued the following news release:
Medulloblastoma (MB) is the most common malignant brain tumor in children, and about one-fourth of children with MB fail to respond to standard treatment. Allison M. Martin, M.D., has received a 5-year, $970,000 grant from the National Institutes of Health to investigate a novel immunotherapy approach that targets B7-H3--a molecule that is highly overexpressed in M . . .
Medulloblastoma (MB) is the most common malignant brain tumor in children, and about one-fourth of children with MB fail to respond to standard treatment. Allison M. Martin, M.D., has received a 5-year, $970,000 grant from the National Institutes of Health to investigate a novel immunotherapy approach that targets B7-H3--a molecule that is highly overexpressed in M . . .